Sanofi-Aventis partly to recall "Clexane inj."

Published: 2006-02-17 06:58:00

Updated: 2006-02-17 06:58:00

Sanofi-Aventis announced to recall about 30 batches of Enoxaparin (Clexane inj.) in 58 countries over the world including Korea, Africa, Asia, Latin America and Europe at a level of keeping its safety according to the intensive survey especially on the over contents of the active ingredient.

...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK